Cheol Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cheol Park has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anindita Basu
University of Chicago
1 shared publication - Atique U. Ahmed
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University
1 shared publication - Charles David James
Northwestern University
1 shared publication Dieter H Heiland
Microenvironment and Immunology Research Laboratory, Medical-Center, University of Freiburg, Freiburg, Germany
1 shared publication- Ella N. Perrault
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
1 shared publication - Eunus S. Ali
Department of Toxicology and Cancer Biology, University of Kentucky
1 shared publication
Latest Publications
- Open Access
- 19 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (20) , eade7236
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production
During therapy, adaptations driven by cellular plasticity are partly responsible for driving the inevitable recurrence of glioblastoma (GBM). To investigate plasticity-induced adaptation during standard-of-care chemotherapy temozolomide (TMZ), we performed in vivo single-cell RNA sequencing in patient-derived xenograft (PDX) tumors of GBM before, during, and after therapy. Comparing single-cell transcriptomic patterns identified distinct cellular populations present during TMZ therapy. Of interest was the increased expression of ribonucleotide reductase regulatory subunit M2 ( RRM2 ), which we found to regulate dGTP and dCTP production vital for DNA damage response during TMZ therapy. Furthermore, multidimensional modeling of spatially resolved transcriptomic and metabolomic analysis in patients’ tissues revealed strong correlations between RRM2 and dGTP. This supports our data that RRM2 regulates the demand for specific dNTPs during therapy. In addition, treatment with the RRM2 inhibitor 3-AP (Triapine) enhances the efficacy of TMZ therapy in PDX models. We present a previously unidentified understanding of chemoresistance through critical RRM2-mediated nucleotide production.
- 19 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (20) , eade7236
Open AccessRibonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production
During therapy, adaptations driven by cellular plasticity are partly responsible for driving the inevitable recurrence of glioblastoma (GBM). To investigate plasticity-induced adaptation during standard-of-care chemotherapy temozolomide (TMZ), we performed in vivo single-cell RNA sequencing in patient-derived xenograft (PDX) tumors of GBM before, during, and after therapy. Comparing single-cell transcriptomic patterns identified distinct cellular populations present during TMZ therapy. Of interest was the increased expression of ribonucleotide reductase regulatory subunit M2 ( RRM2 ), which we found to regulate dGTP and dCTP production vital for DNA damage response during TMZ therapy. Furthermore, multidimensional modeling of spatially resolved transcriptomic and metabolomic analysis in patients’ tissues revealed strong correlations between RRM2 and dGTP. This supports our data that RRM2 regulates the demand for specific dNTPs during therapy. In addition, treatment with the RRM2 inhibitor 3-AP (Triapine) enhances the efficacy of TMZ therapy in PDX models. We present a previously unidentified understanding of chemoresistance through critical RRM2-mediated nucleotide production.